NPPB and pulmonary arterial hypertension: The STELLAR study (NCT04576988), a multicenter, double-blind, phase-3 trial, demonstrated that subcutaneous sotatercept every 3 weeks substantially improved exercise capacity, PVR, NT-proBNP, time to death or clinical worsening, and French risk score during a 24-week period among WHO-FC II-III PAH patients on stable background therapy [109].